ArticleFrontiers in oncology2026
Ganglioneuroblastoma associated with neurofibromatosis type 1: a case report with a systematic review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neurofibromatosis type 1 (NF1) is a hereditary disorder characterized by variable clinical manifestations and a predisposition to tumor development. The occurrence of ganglioneuroblastoma(GNB) in patients with NF1 is rare. Methods: Here, we report a pediatric case and present a review of the relevant literature. Results: A 3-year-old girl presented with progressively enlarging café-au-lait macules since birth and intermittent back and lumbar discomfort. Imaging revealed a mediastinal mass, which was completely resected. Histopathological examination confirmed GNB, and the patient was subsequently referred for adjuvant chemotherapy. Targeted genetic testing identified a heterozygous deletion spanning exons 1-58 of the Discussion: The variant identified in this case has not been previously described, thereby expanding the phenotypic and genotypic spectrum of NF1-related tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.